Legal Representation
Attorney
Alan Taboada
USPTO Deadlines
Next Deadline
73 days remaining
NOA E-Mailed - SOU Required
Due Date
October 15, 2025
Extension Available
Until April 15, 2026
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 15, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 25, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Mar 25, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Mar 25, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Mar 25, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 18, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 18, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 12, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 24, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 23, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 23, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 23, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 4, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 4, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 4, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 29, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 27, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 15, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Culturing of cells for scientific research purposes; Cell culture services for scientific and research purposes, for others; Scientific research in the nature of conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Pharmaceutical research and development; Research and development in the field of pharmaceuticals for the pharmaceutical industry; Research and development in the field of biotechnology; Research and development in the field of diagnostic preparations; Research and development in the field of microorganisms and cells; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research and development services in the field of immunology; Advisory services relating to scientific research; Biochemical research and development; Biomedical research services; Biotechnology research; Chemical research and analysis; Clinical research in the fields of viral disease, cancer, and cell therapy; Consultancy in the field of pharmaceutical research; Consultancy relating to pharmaceutical research and development; Gene therapy research; Laboratory research services relating to pharmaceuticals; Medical research services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Stem cell research; Advisory services relating to gene therapy research
Additional Information
Pseudo Mark
GIAN TCR; GIANT CR; GIANT TCR; GIANT T CELL RECEPTOR
Classification
International Classes
042